Literature DB >> 28077996

Effect of pterostilbene on glioma cells and related mechanisms.

Liang Yu1, Zhendong Zhong2, Hongbin Sun1, Linxia Yan3, Baomin He1, Supin Li1, Shuai Ma1, Lili Yang1, Yulan Huang4.   

Abstract

Neuroglioma is the most common primary malignant tumor in neurosurgery. Due to unfavorable life quality of patients, the treatment of glioma is a major challenge in clinics. The search for effect treatment drugs thus benefits patient prognosis. As one derivative of resveratrol, pterostilbene has a wide spectrum of pharmaceutical functions, especially with the anti-tumor effects. This study thus investigated the effect of pterostilbene on neuroglioma and related mechanisms. U87 glioma cell line was divided into control, normal culture and different dosages of pterostilbene groups, which received 5 mM or 10 mM pterostilbene for 48 h. MTT assay was used to detect U87 cell proliferation, while invasion assay was employed to test the effect of pterostilbene on cell invasion, followed by flow cytometry assay for analyzing U87 cell apoptosis. Real-time PCR was used to test mRNA expression of Bcl-2 and Bax in glioma cells under the effect of pterostilbene, while Western blotting was used to detect alternation of Bcl-2 and Bax protein levels. Pterostilbene significantly inhibited proliferation and invasion abilities of glioma cells compared to those in control group (P<0.05). It can also enhance cell apoptosis, decrease mRNA and protein of Bcl-2 expression, and increase mRNA and protein expressions of Bax (P<0.05 compared to control group) in a dose-dependent manner. Pterostilbene can facilitate apoptosis of glioma cells, and inhibit their proliferation and invasion via mediating apoptotic/anti-apoptotic homeostasis.

Entities:  

Keywords:  Bax; Bcl-2; Glioma; cell invasion; cell proliferation; pterostilbene

Year:  2016        PMID: 28077996      PMCID: PMC5209476     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  23 in total

1.  Activation of ERK1/2 is required for the antimitotic activity of the resveratrol analogue 3,4,5,4'-tetramethoxystilbene (DMU-212) in human melanoma cells.

Authors:  Vasilis Pericles Androutsopoulos; Irene Fragiadaki; Androniki Tosca
Journal:  Exp Dermatol       Date:  2015-05-08       Impact factor: 3.960

Review 2.  Intercellular cooperation and competition in brain cancers: lessons from Drosophila and human studies.

Authors:  Indrayani Waghmare; Austin Roebke; Mutsuko Minata; Madhuri Kango-Singh; Ichiro Nakano
Journal:  Stem Cells Transl Med       Date:  2014-09-17       Impact factor: 6.940

Review 3.  Cancer prevention and therapy through the modulation of the tumor microenvironment.

Authors:  Stephanie C Casey; Amedeo Amedei; Katia Aquilano; Asfar S Azmi; Fabian Benencia; Dipita Bhakta; Alan E Bilsland; Chandra S Boosani; Sophie Chen; Maria Rosa Ciriolo; Sarah Crawford; Hiromasa Fujii; Alexandros G Georgakilas; Gunjan Guha; Dorota Halicka; William G Helferich; Petr Heneberg; Kanya Honoki; W Nicol Keith; Sid P Kerkar; Sulma I Mohammed; Elena Niccolai; Somaira Nowsheen; H P Vasantha Rupasinghe; Abbas Samadi; Neetu Singh; Wamidh H Talib; Vasundara Venkateswaran; Richard L Whelan; Xujuan Yang; Dean W Felsher
Journal:  Semin Cancer Biol       Date:  2015-04-10       Impact factor: 15.707

4.  The resveratrol oligomers, cis- and trans-gnetin H, from Paeonia suffruticosa seeds inhibit the growth of several human cancer cell lines.

Authors:  Ying Gao; Chunnian He; Ran Ran; Dabing Zhang; Dawei Li; Pei-Gen Xiao; Elliot Altman
Journal:  J Ethnopharmacol       Date:  2015-04-09       Impact factor: 4.360

5.  A polymer-protein core-shell nanomedicine for inhibiting cancer migration followed by photo-triggered killing.

Authors:  Ranjith Ramachandran; Giridharan Loghanathan Malarvizhi; Parwathy Chandran; Neha Gupta; Deepthy Menon; Dilip Panikar; Shantikumar Nair; Manzoor Koyakutty
Journal:  J Biomed Nanotechnol       Date:  2014-08       Impact factor: 4.099

6.  Increased sensitivity to ionizing radiation by targeting the homologous recombination pathway in glioma initiating cells.

Authors:  Yi Chieh Lim; Tara L Roberts; Bryan W Day; Brett W Stringer; Sergei Kozlov; Shazrul Fazry; Zara C Bruce; Kathleen S Ensbey; David G Walker; Andrew W Boyd; Martin F Lavin
Journal:  Mol Oncol       Date:  2014-06-27       Impact factor: 6.603

Review 7.  Advances in stem cells, induced pluripotent stem cells, and engineered cells: delivery vehicles for anti-glioma therapy.

Authors:  Jacob S Young; Ramin A Morshed; Julius W Kim; Irina V Balyasnikova; Atique U Ahmed; Maciej S Lesniak
Journal:  Expert Opin Drug Deliv       Date:  2014-07-08       Impact factor: 6.648

8.  Mutation of isocitrate dehydrogenase 1 induces glioma cell proliferation via nuclear factor-κB activation in a hypoxia-inducible factor 1-α dependent manner.

Authors:  Guoliang Wang; Ke Sai; Fanghe Gong; Qunying Yang; Furong Chen; Jian Lin
Journal:  Mol Med Rep       Date:  2014-03-14       Impact factor: 2.952

9.  Pterostilbene and allopurinol reduce fructose-induced podocyte oxidative stress and inflammation via microRNA-377.

Authors:  Wei Wang; Xiao-Qin Ding; Ting-Ting Gu; Lin Song; Jian-Mei Li; Qiao-Chu Xue; Ling-Dong Kong
Journal:  Free Radic Biol Med       Date:  2015-03-05       Impact factor: 7.376

Review 10.  A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy.

Authors:  Dong-Sup Chung; Hye-Jin Shin; Yong-Kil Hong
Journal:  J Immunol Res       Date:  2014-06-09       Impact factor: 4.818

View more
  2 in total

1.  High Expression of CISD2 in Relation to Adverse Outcome and Abnormal Immune Cell Infiltration in Glioma.

Authors:  Fang Zhang; Hua-Bao Cai; Han-Ze Liu; Shen Gao; Bin Wang; Yang-Chun Hu; Hong-Wei Cheng; Jin-Xiu Liu; Yang Gao; Wen-Ming Hong
Journal:  Dis Markers       Date:  2022-04-21       Impact factor: 3.464

2.  Stoichioproteomics reveal oxygen usage bias, key proteins and pathways in glioma.

Authors:  Yongqin Yin; Bo Li; Kejie Mou; Muhammad T Khan; Aman C Kaushik; Dongqing Wei; Yu-Juan Zhang
Journal:  BMC Med Genomics       Date:  2019-08-29       Impact factor: 3.063

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.